Bouchemla Fayssal, Agoltsov Valery Alexandrovich, Veselovsky Stepan Yuryevich, Larionov Sergey Vasilyevich, Popova Olga Mikhaylovna, Krivenko Dmitry Valentinovich
Department of Animal Disease, Veterinarian and Sanitarian Expertise, Faculty of Veterinary Medicine, Vavilov Saratov State Agrarian University, Saratov, Russia.
Department of Food Technology, Faculty of Veterinary Medicine, Vavilov Saratov State Agrarian University, Saratov, Russia.
Vet World. 2019 Apr;13(4):758-763. doi: 10.14202/vetworld.2020.758-763. Epub 2020 Apr 22.
The aim of the study was to obtain a vaccine against animal brucellosis having high immunogenic properties by carrying an evaluation of the effectiveness of split-conjugated animal brucellosis vaccine combined with fosprenil and polypeptide C as a molecular immunomodulatory adjuvant according to the results of serological studies of the blood of animals: Agglutination reaction, complement fixation, and rose Bengal sample.
Eighteen calves of Holstein Friesians breed, aged 5 months, with a living weight of 100-150 kg, were divided into three groups of six animals each. All animals were healthy and they received a prophylactic vaccination against brucellosis. The dry split-conjugated vaccine against brucellosis in animals was dissolved in saline and for this purpose, 10 ml of saline was poured into the vaccine vial. Then the content was mixed, and afterward 1 ml was used per animal. Fosprenil was used at the rate of 1 kg of animal weight: 100 kg (calf weight) was multiplied by 0.05 (dose/1 kg of animal weight); 5 ml of fosprenil was obtained, which was collected into disposable syringes and intramuscularly sterilely injected into the croup area.Calves in the first group (control) were intramuscularly injected with the vaccine at a dose of 1.0 ml, and fosprenil at a dose of 5.0 ml was administered intramuscularly once to the croup area. Animals from the second group were subcutaneously immunized by the vaccine with polypeptide C at a dose of 1.0 ml. Polypeptide C is a solution that was poured into a vial with a vaccine at a dose of 10.0 ml, the content was mixed, and then calves were injected subcutaneously into the middle third of the neck in 1 ml (10 doses in a vial).Immunization of calves in the third group was carried out with a vaccine, diluted with an isotonic sodium chloride solution of 0.9%, at a dose of 1.0 ml subcutaneously once. At the 14, 30, and 90 days after vaccination, a blood sampling was taken for serological tests: Agglutination test, complement fixation test, and rose Bengal test.
After conducting serological studies, it was noted that split-conjugated vaccine against animal brucellosis using fosprenil forms antibodies in large titers and they persist for a longer time in the body of animals compared to the other tested vaccine: The first combination with the immunomodulatory polypeptide C and the vaccine only on the physiological solution.
The developed complex of split-conjugated vaccine against brucellosis in animals enhances the humoral immune response of the organism against brucellosis and improves the protection of animals against the disease when it is used with the immunomodulatory fosprenil. In the future, we want to expand the use of the resulting complex in the fight against brucellosis on a larger population and to study the change in cellular immunity after the introduction of the resulting complex on an animal organism.
本研究的目的是通过根据动物血液的血清学研究结果（凝集反应、补体结合和玫瑰红试验）评估与磷苯尼酸和多肽C作为分子免疫调节佐剂联合使用的裂解共轭动物布鲁氏菌病疫苗的有效性，从而获得一种具有高免疫原性的抗动物布鲁氏菌病疫苗。
18头5月龄、体重100 - 150 kg的荷斯坦弗里生犊牛被分为三组，每组6头。所有动物均健康，并接受了布鲁氏菌病预防性疫苗接种。将动物用冻干裂解共轭布鲁氏菌病疫苗溶解于生理盐水中，为此，向疫苗瓶中倒入10 ml生理盐水。然后将内容物混合，之后每头动物使用1 ml。磷苯尼酸的使用剂量为每千克动物体重：100 kg（犊牛体重）乘以0.05（每千克动物体重剂量）；得到5 ml磷苯尼酸，将其收集到一次性注射器中，并在臀部区域进行无菌肌肉注射。第一组（对照组）犊牛肌肉注射1.0 ml剂量的疫苗，并在臀部区域一次性肌肉注射5.0 ml剂量的磷苯尼酸。第二组动物皮下注射含多肽C的1.0 ml剂量疫苗。多肽C是一种溶液，以10.0 ml的剂量倒入装有疫苗的瓶中，将内容物混合，然后犊牛在颈部中三分之一处皮下注射1 ml（一瓶中有10剂）。第三组犊牛用0.9%的等渗氯化钠溶液稀释的疫苗进行皮下免疫，剂量为1.0 ml，注射一次。在接种疫苗后的第14、30和90天，采集血液进行血清学检测：凝集试验、补体结合试验和玫瑰红试验。
进行血清学研究后发现，与其他测试疫苗相比，使用磷苯尼酸的抗动物布鲁氏菌病裂解共轭疫苗能形成高滴度抗体，且在动物体内持续时间更长：第一种是与免疫调节多肽C联合使用，第二种是仅使用生理溶液稀释的疫苗。
所研发的抗动物布鲁氏菌病裂解共轭疫苗复合物增强了机体对布鲁氏菌病的体液免疫反应，并在与免疫调节磷苯尼酸联合使用时提高了动物对该疾病的保护作用。未来，我们希望扩大所得到的复合物在更大群体中对抗布鲁氏菌病的应用，并研究将该复合物引入动物机体后细胞免疫的变化。
